To study the genetic effects of various inflammatory cytokines on peritoneal solute transport rate (PSTR) in incident Korean peritoneal dialysis (PD) patients.
Design
Case-control association study.
Methods
132 patients with baseline peritoneal equilibration test within 1 – 3 months after starting PD were enrolled. We analyzed the influence of single nucleotide polymorphisms (SNPs) of interleukin-6 (IL-6; -572G/C, T15A), tumor necrosis factor-alpha (TNF-α; -1031C/T, -863C/A, -308G/A), and IL-10 (-1082A/G, -592A/C) on baseline PSTR. Clinical parameters such as age, gender, presence of diabetes mellitus, comorbidity, C-reactive protein, and residual renal function were also included as covariates.
Results
The T15A SNP of IL-6 (rs13306435) was associated with PSTR. Patients with TA genotype (n = 18) had significantly lower D4/P creatinine (0.65 ± 0.087 vs 0.73 ± 0.110, p = 0.0046) and higher D4/D0 glucose (0.39 ± 0.174 vs 0.31 ± 0.119, p = 0.027) than patients with TT genotype (n = 114). The log value of the dialysate appearance rate of IL-6 had a strong positive correlation with D4/P creatinine (r2 = 0.1294, p < 0.0001) and was significantly lower in the TA genotype than the TT genotype (201.7 ± 14.42 vs 116.8 ± 88.91 pg/minute, p = 0.0358). By multiple logistic regression, TA genotype was negatively associated with a higher PSTR (high or high average; odds ratio 0.18; 95% confidence interval 0.048 – 0.666).
Conclusions
In incident Korean PD patients, T15A polymorphism of IL-6 is associated with dialysate IL-6 concentration and baseline PSTR.
ChurchillD.N., ThorpeK.E., NolphK.D., KeshaviahP.R., OreopoulosD.G., PageD.Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group.J Am Soc Nephrol1998; 9: 1285–92.
2.
WangT., HeimburgerO., WaniewskiJ., BergstromJ., LindholmB.Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients.Nephrol Dial Transplant1998; 13: 1242–9.
3.
RumpsfeldM., McDonaldS.P., JohnsonD.W.Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations.J Am Soc Nephrol2006; 17: 271–8.
4.
BrimbleK.S., WalkerM., MargettsP.J., KundhalK.K., RabbatC.G.Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis.J Am Soc Nephrol2006; 17: 2591–8.
5.
HeafJ.Pathogenic effects of a high peritoneal transport rate.Semin Dial2000; 13: 188–93.
6.
RumpsfeldM., McDonaldS.P., PurdieD.M., CollinsJ., JohnsonD.W.Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients.Am J Kidney Dis2004; 43: 492–501.
7.
StenvinkelP., KettelerM., JohnsonR.J., LindholmB., Pecoits-FilhoR., RiellaM.IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly.Kidney Int2005; 67: 1216–33.
8.
Pecoits-FilhoR., AraujoM.R., LindholmB., StenvinkelP., AbensurH., RomaoJ.E.Jr.Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate.Nephrol Dial Transplant2002; 17: 1480–6.
9.
GillerotG., GoffinE., MichelC., EvenepoelP., van BiesenW., TintillierM.Genetic and clinical factors influence the baseline permeability of the peritoneal membrane.Kidney Int2005; 67: 2477–87.
10.
SmitW., van DijkP., LangedijkM.J., SchoutenN., van den BergN., StruijkD.G.Peritoneal function and assessment of reference values using a 3.86% glucose solution.Perit Dial Int2003; 23: 440–9.
11.
Du BoisD., Du BoisE.F.A formula to estimate the approximate surface area if height and weight be known. 1916.Nutrition1989; 5: 303–11; Discussion: 312–13.
12.
RajD.S., LangosV., GangamN., RoscoeJ.Ethnic variability in peritoneal equilibration test and urea kinetics.Am J Kidney Dis1997; 30: 374–81.
13.
SelgasR., BajoM.A., CirugedaA., del PesoG., ValdesJ., CastroM.J.Ultrafiltration and small solute transport at initiation of PD: questioning the paradigm of peritoneal function.Perit Dial Int2005; 25: 68–76.
14.
NakamotoH., ImaiH., KawanishiH., NakamotoM., MinakuchiJ., KumonS.Effect of diabetes on peritoneal function assessed by personal dialysis capacity test in patients undergoing CAPD.Am J Kidney Dis2002; 40: 1045–54.
15.
SelgasR., BajoM.A., CastroM.J., del PesoG., AguileraA., Fernandez-PerpenA.Risk factors responsible for ultrafiltration failure in early stages of peritoneal dialysis.Perit Dial Int2000; 20: 631–6.
16.
RubinJ., RustP., BrownP., PopovichR.P., NolphK.D.A comparison of peritoneal transport in patients with psoriasis and uremia.Nephron1981; 29: 185–9.
17.
DaviesS.J., PhillipsL., NaishP.F., RussellG.I.Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival.Nephrol Dial Transplant2002; 17: 1085–92.
18.
DaviesS.J.Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients.Kidney Int2004; 66: 2437–45.
19.
AxelssonJ., DevuystO., NordforsL., HeimburgerO., StenvinkelP., LindholmB.Place of genotyping and phenotyping in understanding and potentially modifying outcomes in peritoneal dialysis patients.Kidney Int Suppl2006; 103: S138–45.
20.
SzetoC.C., PoonP., SzetoC.Y., WongT.Y., LaiK.B., LiP.K.Plasminogen activator inhibitor-1 4G/5G genetic polymorphism does not affect peritoneal transport characteristic.Am J Kidney Dis2002; 39: 1061–7.
21.
WongT.Y., SzetoC.C., SzetoC.Y., LaiK.B., ChowK.M., LiP.K.Association of eNOS polymorphism with basal peritoneal membrane function in uremic patients.Am J Kidney Dis2003; 42: 781–6.
22.
SzetoC.C., ChowK.M., PoonP., SzetoC.Y.K., WongT.Y.H., LiP.K.T.Genetic polymorphism of VEGF: impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients.Kidney Int2004; 65: 1947–55.
23.
ChungS.H., HeimburgerO., StenvinkelP., BergstromJ., LindholmB.Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis.Nephrol Dial Transplant2001; 16: 2240–5.
24.
MargettsP.J., McMullinJ.P., RabbatC.G., ChurchillD.N.Peritoneal membrane transport and hypoalbuminemia: cause or effect?Perit Dial Int2000; 20: 14–18.
25.
Pecoits-FilhoR., CarvalhoM.J., StenvinkelP., LindholmB., HeimburgerO.Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis.Perit Dial Int2006; 26: 53–63.
26.
OhK.H., MoonJ.Y., OhJ., KimS.G., HwangY.H., KimS.Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients.Nephrol Dial Transplant2008; 23: 2356–64.
27.
WitowskiJ., JorresA., ColesG.A., WilliamsJ.D., TopleyN.Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA.Kidney Int1996; 50: 1212–23.
28.
van EschS., ZweersM.M., JansenM.A., de WaartD.R., van ManenJ.G., KredietR.T.Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients.Perit Dial Int2004; 24: 554–61.
29.
RodriguesA.S., AlmeidaM., FonsecaI., MartinsM., CarvalhoM.J., SilvaF.Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated with systemic inflammation.Nephrol Dial Transplant2006; 21: 763–9.
30.
RodriguesA.S., MartinsM., KorevaarJ.C., SilvaS., OliveiraJ.C., CabritaA.Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters.Am J Nephrol2007; 27: 84–91.
31.
TerryC.F., LoukaciV., GreenF.R.Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation.J Biol Chem2000; 275: 18138–44.
32.
Noponen-HietalaN., VirtanenI., KarttunenR., SchwenkeS., JakkulaE., LiH.Genetic variations in IL6 associate with intervertebral disc disease characterized by sciatica.Pain2005; 114(1-2): 186–94.
